FI104719B - Förfarande för framställning av en terapeutiskt användbar förening - Google Patents
Förfarande för framställning av en terapeutiskt användbar förening Download PDFInfo
- Publication number
- FI104719B FI104719B FI922344A FI922344A FI104719B FI 104719 B FI104719 B FI 104719B FI 922344 A FI922344 A FI 922344A FI 922344 A FI922344 A FI 922344A FI 104719 B FI104719 B FI 104719B
- Authority
- FI
- Finland
- Prior art keywords
- preparation
- compounds
- compound
- mixture
- concentrated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Pyrrole Compounds (AREA)
Claims (5)
1. Förfarande för framställning av en terapeutiskt användbar förening med formeln I 5 Ph -AA-C^-Y-R1 (A N A 1-1 111 10. väri Y är en direkt bindning, -CH2-, -(CH2)2-, -CH20- el-ler -CH2S-; och R1 är en grupp med formeln: 15 •OC ·““ XX) 20 väri <]· R2 och R3 envar är självständigt H, OH eller halogen och 25. och X1 är envar självständigt O eller CH2; • · eller av dess farmaceutiskt godtagbart sait, k ä n n e - *: t e c k n a t därav, att man • · · Ά* (a) omsätter en förening med formeln II • · · • · · Ph 30 f ^-f N-H I (II) (An A) - *: i H ...f med en förening med formeln 35 Q-CH2-Y-R1 • · • · « I M • · m i 37 104719 väri Y och R1 är säsom ovan definierats och Q är en avgä-ende grupp, eller (b) cykliserar en förening med formeln IV Ph 5
9-Y-R1 ncch2ch2 _I (IV) väri Y och R1 är säsom ovan definierats, geriom uppvärmning 10 med en koncentrerad mineralsyra, och efter nämnda förfarande (a) eller (b) , valfritt, omvandlar produkten till ett farmaceutiskt godtagbart salt.
2. Förfarande enligt patentkrav 1, kanne-15 tecknat därav, att i förfarande (a), är Q Cl, Br, I eller metansulfonyloxi, och omsättningen utförs i närvaro av en syraacceptor och att i förfarande (b) är den koncentrerade mineralsyran en koncentrerad saltsyra.
3. Förfarande enligt patentkrav 1 eller 2, k ä n-20 netecknat därav, att man framställer en förening med formeln I, väri R1 är: i £K> 25 « « 1 • · *. 1.
4. Förfarande enligt nägot av de föregäende patent- * 1 kraven, kännetecknat därav, att man framstäl- * · · ’· ler en förening med formeln I, väri Y är en direkt bind- • « V1 ning, -CH2- eller - (CH2) 2-. 30
5. Förfarande enligt patentkrav 4, k ä n n e - • ♦ · . _ • tecknat därav, att man framställer en förening med formeln I, väri Y är -CH2-. • · · < « · • I · • · # « · · • · « · · • » • ·
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8928041 | 1989-12-12 | ||
| GB898928041A GB8928041D0 (en) | 1989-12-12 | 1989-12-12 | Muscarinic receptor antagonists |
| PCT/EP1990/002042 WO1991009015A1 (en) | 1989-12-12 | 1990-11-28 | Muscarinic receptor antagonists |
| EP9002042 | 1990-11-28 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI922344A FI922344A (fi) | 1992-05-22 |
| FI922344A0 FI922344A0 (fi) | 1992-05-22 |
| FI104719B true FI104719B (sv) | 2000-03-31 |
Family
ID=10667812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI922344A FI104719B (sv) | 1989-12-12 | 1992-05-22 | Förfarande för framställning av en terapeutiskt användbar förening |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5281601A (sv) |
| EP (1) | EP0505377B1 (sv) |
| JP (1) | JPH0684370B2 (sv) |
| AT (1) | ATE132488T1 (sv) |
| CA (1) | CA2067816C (sv) |
| DE (1) | DE69024663T2 (sv) |
| DK (1) | DK0505377T3 (sv) |
| ES (1) | ES2082013T3 (sv) |
| FI (1) | FI104719B (sv) |
| GB (1) | GB8928041D0 (sv) |
| GR (1) | GR3019036T3 (sv) |
| IE (1) | IE70733B1 (sv) |
| PT (1) | PT96143B (sv) |
| WO (1) | WO1991009015A1 (sv) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5932594A (en) * | 1988-11-01 | 1999-08-03 | Pfizer, Inc. | Muscarinic receptor antagonists |
| US6693202B1 (en) * | 1999-02-16 | 2004-02-17 | Theravance, Inc. | Muscarinic receptor antagonists |
| AU779870B2 (en) * | 2000-01-20 | 2005-02-17 | Eisai R&D Management Co., Ltd. | Nitrogenous cyclic compounds and pharmaceutical compositions containing the same |
| BR0215801A (pt) | 2002-07-08 | 2005-05-10 | Ranbaxy Lab Ltd | Derivados de 3,6-dissubstituìdos azabiciclo [3.1.0] hexano úteis como antagonistas de receptores muscarìnicos |
| US7265147B2 (en) * | 2002-07-31 | 2007-09-04 | Ranbaxy Laboratories Limited | 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists |
| EP1545508A4 (en) * | 2002-08-09 | 2009-11-25 | Ranbaxy Lab Ltd | 3,6-DISUBSTITUTED AZABICYCLO ¬3.1.0 HEXANE DERIVATIVES AS USEFUL AS MUSCARINIC RECEPTOR AGONISTS |
| CN1688544A (zh) * | 2002-08-23 | 2005-10-26 | 兰贝克赛实验室有限公司 | 作为蕈毒碱受体拮抗剂的含氟代和磺酰氨基的3,6－二取代的氮杂双环(3.1.0)己烷衍生物 |
| TW200800953A (en) * | 2002-10-30 | 2008-01-01 | Theravance Inc | Intermediates for preparing substituted 4-amino-1-(pyridylmethyl) piperidine |
| US7232835B2 (en) * | 2002-12-10 | 2007-06-19 | Ranbaxy Laboratories Limited | 3,6-Disubstituted azabicyclo derivatives as muscarinic receptor antagonists |
| US7465751B2 (en) * | 2002-12-23 | 2008-12-16 | Ranbaxy Laboratories Limited | 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists |
| ATE386738T1 (de) * | 2002-12-23 | 2008-03-15 | Ranbaxy Lab Ltd | Flavaxat-derivate als muscarin-rezeptor antagonisten |
| US7488748B2 (en) | 2003-01-28 | 2009-02-10 | Ranbaxy Laboratories Limited | 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
| WO2004089898A1 (en) * | 2003-04-09 | 2004-10-21 | Ranbaxy Laboratories Limited | Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
| DE60313898T2 (de) * | 2003-04-10 | 2008-01-17 | Ranbaxy Laboratories, Ltd. | Substituierte azabicyclo hexane derivate als muscarin rezeptor antagonisten |
| WO2004089899A1 (en) | 2003-04-10 | 2004-10-21 | Ranbaxy Laboratories Limited | Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
| CN100436414C (zh) * | 2003-04-11 | 2008-11-26 | 兰贝克赛实验室有限公司 | 作为毒蕈碱受体拮抗剂的氮杂双环衍生物 |
| WO2005007645A1 (en) * | 2003-07-11 | 2005-01-27 | Theravance, Inc. | Substituted 4-amino-1-benzylpiperidine compounds |
| US7234991B2 (en) * | 2004-05-10 | 2007-06-26 | Firecode Ltd. | Moving toy |
| WO2006005980A1 (en) * | 2004-06-16 | 2006-01-19 | Ranbaxy Laboratories Limited | Xanthine derivatives useful as muscarinic receptor antagonists |
| WO2006018708A2 (en) * | 2004-08-19 | 2006-02-23 | Ranbaxy Laboratories Limited | Pyrrolidine derivatives as muscarinic receptor antagonists |
| EP1794161A2 (en) * | 2004-09-24 | 2007-06-13 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
| EP1797040A1 (en) * | 2004-09-29 | 2007-06-20 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
| WO2006054162A1 (en) * | 2004-11-19 | 2006-05-26 | Ranbaxy Laboratories Limited | Azabicyclic muscarinic receptor antagonists |
| US20100035954A1 (en) * | 2004-12-15 | 2010-02-11 | Mohammad Salman | Acid addition salts of muscarinic receptor antagonists |
| EP1888525A1 (en) * | 2005-05-03 | 2008-02-20 | Ranbaxy Laboratories Limited | 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives as muscarinic receptor antagonists |
| WO2007045979A1 (en) | 2005-10-19 | 2007-04-26 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of muscarinic receptor antagonists |
| US20090010923A1 (en) * | 2007-04-24 | 2009-01-08 | University Of Maryland, Baltimore | Treatment of cancer with anti-muscarinic receptor agents |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3125578A (en) * | 1962-05-17 | 1964-03-17 | xxviii | |
| GB1455687A (en) * | 1972-12-28 | 1976-11-17 | Aspro Nicholas Ltd | Pharmacologically active 3-phenyl-3-aminoalkyl-2,6-dioxo-hydro genated pyridines |
| DE3835291A1 (de) * | 1988-04-19 | 1989-11-02 | Bayer Ag | 1,3-disubstituierte pyrrolidine |
-
1989
- 1989-11-28 US US07/859,489 patent/US5281601A/en not_active Expired - Fee Related
- 1989-12-12 GB GB898928041A patent/GB8928041D0/en active Pending
-
1990
- 1990-11-28 DK DK90917074.8T patent/DK0505377T3/da active
- 1990-11-28 AT AT90917074T patent/ATE132488T1/de not_active IP Right Cessation
- 1990-11-28 EP EP90917074A patent/EP0505377B1/en not_active Expired - Lifetime
- 1990-11-28 CA CA002067816A patent/CA2067816C/en not_active Expired - Fee Related
- 1990-11-28 DE DE69024663T patent/DE69024663T2/de not_active Expired - Fee Related
- 1990-11-28 ES ES90917074T patent/ES2082013T3/es not_active Expired - Lifetime
- 1990-11-28 JP JP2515785A patent/JPH0684370B2/ja not_active Expired - Fee Related
- 1990-11-28 WO PCT/EP1990/002042 patent/WO1991009015A1/en active IP Right Grant
- 1990-12-10 PT PT96143A patent/PT96143B/pt not_active IP Right Cessation
- 1990-12-11 IE IE446290A patent/IE70733B1/en not_active IP Right Cessation
-
1992
- 1992-05-22 FI FI922344A patent/FI104719B/sv active
-
1996
- 1996-02-21 GR GR960400439T patent/GR3019036T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE69024663T2 (de) | 1996-05-15 |
| IE70733B1 (en) | 1996-12-11 |
| DE69024663D1 (de) | 1996-02-15 |
| US5281601A (en) | 1994-01-25 |
| FI922344A (fi) | 1992-05-22 |
| ES2082013T3 (es) | 1996-03-16 |
| DK0505377T3 (da) | 1996-02-05 |
| JPH0684370B2 (ja) | 1994-10-26 |
| WO1991009015A1 (en) | 1991-06-27 |
| CA2067816A1 (en) | 1991-06-13 |
| EP0505377A1 (en) | 1992-09-30 |
| JPH05501555A (ja) | 1993-03-25 |
| FI922344A0 (fi) | 1992-05-22 |
| GB8928041D0 (en) | 1990-02-14 |
| EP0505377B1 (en) | 1996-01-03 |
| PT96143A (pt) | 1991-09-30 |
| IE904462A1 (en) | 1991-06-19 |
| GR3019036T3 (en) | 1996-05-31 |
| PT96143B (pt) | 1997-05-28 |
| CA2067816C (en) | 1997-03-25 |
| ATE132488T1 (de) | 1996-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI104719B (sv) | Förfarande för framställning av en terapeutiskt användbar förening | |
| AU614224B2 (en) | Pyrrolidine derivatives | |
| US5340831A (en) | Muscarinic receptor antagonists | |
| JP2008525357A (ja) | 抗ムスカリン活性を有するアゾール誘導体 | |
| US5418229A (en) | Muscarinic receptor antagonists | |
| EP0508988B1 (en) | Muscarinic receptor antagonists | |
| EP0441852B1 (en) | Muscarinic receptor antagonists | |
| FI97131B (sv) | Förfarande för framställning av terapeutiskt aktiva piperidinderivat | |
| US5607950A (en) | Muscarinic receptor antagonists | |
| US5932594A (en) | Muscarinic receptor antagonists | |
| EP0505379B1 (en) | Muscarinic receptor antagonists | |
| EP0508995B1 (en) | Muscarinic receptor antagonists |